United Pharm
Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to app… Read more
United Pharm (033270) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.027x
Based on the latest financial reports, United Pharm (033270) has a cash flow conversion efficiency ratio of 0.027x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩11.36 Billion) by net assets (₩421.86 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
United Pharm - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how United Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
United Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of United Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
West Coast Paper Mills Limited
NSE:WSTCSTPAPR
|
0.024x |
|
DOHOME
BK:DOHOME-R
|
N/A |
|
StealthGas Inc
NASDAQ:GASS
|
0.023x |
|
Qingdao Richen Food Co Ltd
SHG:603755
|
0.033x |
|
Sangamo Therapeutics Inc
NASDAQ:SGMO
|
-4.565x |
|
Nantong Xingqiu Graphite Co. Ltd. A
SHG:688633
|
0.024x |
|
Zhejiang Xinzhonggang Thermal Power Co Ltd
SHG:605162
|
0.047x |
|
Jiangsu Hengshang Energy Conservation Technology Co. Ltd. A
SHG:603137
|
N/A |
Annual Cash Flow Conversion Efficiency for United Pharm (2011–2024)
The table below shows the annual cash flow conversion efficiency of United Pharm from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩406.21 Billion | ₩26.79 Billion | 0.066x | -49.81% |
| 2023-12-31 | ₩378.68 Billion | ₩49.77 Billion | 0.131x | -30.38% |
| 2022-12-31 | ₩337.86 Billion | ₩63.78 Billion | 0.189x | +28.77% |
| 2021-12-31 | ₩300.71 Billion | ₩44.09 Billion | 0.147x | +9.82% |
| 2020-12-31 | ₩276.89 Billion | ₩36.96 Billion | 0.133x | -10.75% |
| 2019-12-31 | ₩255.10 Billion | ₩38.15 Billion | 0.150x | -7.30% |
| 2018-12-31 | ₩228.48 Billion | ₩36.86 Billion | 0.161x | +17.54% |
| 2017-12-31 | ₩201.68 Billion | ₩27.68 Billion | 0.137x | -18.90% |
| 2016-12-31 | ₩177.39 Billion | ₩30.02 Billion | 0.169x | +28.50% |
| 2014-12-31 | ₩161.83 Billion | ₩21.31 Billion | 0.132x | -1.80% |
| 2013-12-31 | ₩141.44 Billion | ₩18.97 Billion | 0.134x | -18.19% |
| 2012-12-31 | ₩133.48 Billion | ₩21.88 Billion | 0.164x | -32.90% |
| 2011-12-31 | ₩113.04 Billion | ₩27.62 Billion | 0.244x | -- |